GlassScriptPhysician profile
Serena N Vance
NPI 1699086314
$1,692.56
in general payments reported to CMS, 2019-2025
23 companies · $144 in 2025
The $144 reported for 2025 was less than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $167 · 2022: $338 · 2023: $701 · 2024: $343 · 2025: $144.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $689 · Travel and Lodging: $498.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $689.18 |
| Travel and Lodging | $498.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hologic Sales and Service, LLC | $512.18 | 2023-2024 | Acessa Provu System |
| Abbvie INC. | $199.45 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $115.34 | 2022-2025 | |
| Astellas Pharma US INC | $113.30 | 2022-2023 | Veozah |
| Mayne Pharma Commercial LLC | $98.41 | 2022-2025 | |
| Aspira Women'S Health INC | $81.77 | 2021 | |
| Channel Medsystems, INC. | $70.70 | 2024 | |
| Conmed Corporation | $62.22 | 2025 | Airseal |
| Boston Scientific Corporation | $58.35 | 2023-2024 | Advantage System, Upsylon |
| Coopersurgical, INC. | $56.57 | 2022-2024 | Paragard T 380a, Paragard T 380a |
| Exeltis, USA INC. | $54.55 | 2022-2024 | Slynd |
| Biogen, INC. | $52.54 | 2024 | Zurzuvae |
| Organon LLC | $41.17 | 2022-2025 | Nexplanon |
| Coloplast Corp | $34.29 | 2024-2025 | |
| Abbott Laboratories | $23.22 | 2024 | Assurity |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $19.86 | 2024 | Injectafer |
| Mylan Pharmaceuticals INC. | $15.47 | 2022 | |
| Amgen INC. | $15.27 | 2023 | Prolia, Evenity |
| Merck Sharp & Dohme LLC | $15.21 | 2023 | Gardasil 9 |
| Pfizer INC. | $14.05 | 2025 | |
| Millicent US INC | $13.76 | 2025 | Femlyv, Intrarosa |
| Idorsia Pharmaceuticals US INC | $12.57 | 2022 | |
| Therapeuticsmd, INC. | $12.31 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Serena Vance listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.